From: Frese, Bradford C. <Bradford.Frese@arentfox.com>

Sent: Monday, May 02, 2016 2:35 PM

To: Frank Calvosa

Cc: Berman, Richard; Carlan, Janine; Matt Ruedy; Steve Maddox; Nick Cerrito; Eric Stops;

Evangeline Shih; Gabriel Brier; Lyndsey Przybylski; John V Biernacki; David Cochran

Subject: RE: IPR2015-01903

Frank,

Your proposal is acceptable to Petitioners. We do, however, reserve the right to depose any new individuals making declarations that Patent Owner submits with their response.

Best regards, Bradford

Bradford C. Frese

Associate

Arent Fox LLP | Attorneys at Law 1717 K Street, NW Washington, DC 20006-5344 202.857.6496 DIRECT | 202.857.6395 FAX bradford.frese@arentfox.com | www.arentfox.com

From: Frank Calvosa [mailto:FrankCalvosa@quinnemanuel.com]

Sent: Monday, May 02, 2016 10:46 AM

To: Frese, Bradford C. <Bradford.Frese@arentfox.com>

Cc: Berman, Richard <Richard.Berman@arentfox.com>; Carlan, Janine <Janine.Carlan@arentfox.com>; Matt Ruedy <MRuedy@meiplaw.com>; Steve Maddox <smaddox@meiplaw.com>; Nick Cerrito <NickCerrito@quinnemanuel.com>; Eric Stops <EricStops@quinnemanuel.com>; Evangeline Shih <EvangelineShih@quinnemanuel.com>; Gabriel Brier <GabrielBrier@quinnemanuel.com>; Lyndsey Przybylski <lyndseyprzybylski@quinnemanuel.com>; John V Biernacki <jvbiernacki@JonesDay.com>; David Cochran <dcochran@JonesDay.com>

Subject: Re: IPR2015-01903

Bradford,

Please provide a response by 3 pm today.

Thanks,

Frank

On Apr 27, 2016, at 11:04 PM, Frese, Bradford C. < Bradford.Frese@arentfox.com > wrote:

Frank:

We are considering Patent Owner's offer and will get back to you shortly.

Ract ranardo



Bradford

Bradford C. Frese

Associate

Arent Fox LLP | Attorneys at Law
1717 K Street, NW
Washington, DC 20006-5344
202.857.6496 DIRECT | 202.857.6395 FAX
bradford.frese@arentfox.com | www.arentfox.com

From: Frank Calvosa [mailto:FrankCalvosa@quinnemanuel.com]

Sent: Wednesday, April 27, 2016 5:52 PM

To: Frese, Bradford C. <Bradford.Frese@arentfox.com>; Berman, Richard

< Richard. Berman@arentfox.com >; Carlan, Janine < Janine. Carlan@arentfox.com >; Matt Ruedy

<<u>MRuedy@meiplaw.com</u>>; Steve Maddox <<u>smaddox@meiplaw.com</u>>

Cc: Nick Cerrito < NickCerrito@quinnemanuel.com >; Eric Stops < EricStops@quinnemanuel.com >;

Evangeline Shih <EvangelineShih@quinnemanuel.com>; Gabriel Brier

<<u>GabrielBrier@quinnemanuel.com</u>>; Lyndsey Przybylski <<u>lyndseyprzybylski@quinnemanuel.com</u>>; John

V Biernacki < <u>ivbiernacki@JonesDay.com</u>>; David Cochran < <u>dcochran@JonesDay.com</u>>

Subject: Re: IPR2015-01903

Counsel,

Please let us know whether you agree to Jazz's proposal in the email below. If not, please provide your availability for a call with the Board to further discuss this issue.

Regards,

Frank

On Apr 20, 2016, at 4:57 PM, Frank Calvosa <FrankCalvosa@guinnemanuel.com> wrote:

Counsel,

The issues for the instituted claims in IPR2015-01903 (the "'963 IPR") and IPR2015-00545, -546, -547, -548, -551, -554 (the "REMS IPRs") are overlapping. In an effort to conserve the parties' resources, please let us know whether Petitioners agree to Patent Owner using Dr. Valuck's deposition testimony, from the REMS IPRs, in the '963 IPR. In exchange, Patent Owner will agree to forego Dr. Valuck's deposition in the '963 IPR, related to his opening declaration. Patent Owner will also agree that Dr. DiPiro's and Dr. Bergeron's deposition testimony from the REMS IPRs can be used in the '963 IPR, and that Patent Owner will rely only on Dr. DiPiro's and Dr. Bergeron's previously disclosed onlines, from the REMS IPRs, in the '963 IPR.



Please let us know your response by Tuesday, April 26.

Regards,

Frank Calvosa
Associate
Quinn Emanuel Urquhart & Sullivan, LLP

51 Madison Avenue, 22nd Floor New York, NY 10010 212-849-7569 Direct 212-849-7000 Main Office Number 212-849-7100 FAX frankcalvosa@quinnemanuel.com www.quinnemanuel.com

NOTICE: The information contained in this e-mail message is intended only for the personal and confidential use of the recipient(s) named above. This message may be an attorney-client communication and/or work product and as such is privileged and confidential. If the reader of this message is not the intended recipient or agent responsible for delivering it to the intended recipient, you are hereby notified that you have received this document in error and that any review, dissemination, distribution, or copying of this message is strictly prohibited. If you have received this communication in error, please notify us immediately by e-mail, and delete the original message.

CONFIDENTIALITY NOTICE: This e-mail and any attachments are for the exclusive and confidential use of the intended recipient. If you received this in error, please do not read, distribute, or take action in reliance upon this message. Instead, please notify us immediately by return e-mail and promptly delete this message and its attachments from your computer system. We do not waive attorney-client or work product privilege by the transmission of this message.

CONFIDENTIALITY NOTICE: This e-mail and any attachments are for the exclusive and confidential use of the intended recipient. If you received this in error, please do not read, distribute, or take action in reliance upon this message. Instead, please notify us immediately by return e-mail and promptly delete this message and its attachments from your computer system. We do not waive attorney-client or work product privilege by the transmission of this message.

